/ /


FDA should provide better education about biosimilar drugs on the agency’s web site dedicated to biosimilars, a patient advocacy group said.
Understanding the key barriers to biosimilar adoption in the U.S. is the first step managed care executives can take to overcome these obstacles, according to a Trinity Parners report.
How are generic prices changing, how will biosimilars impact costs, and what changes out of Washington should healthcare executives watch? Economics guru Joe Fuhr weighs in.
This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.
More targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.
Dermatologists need to be aware of margin of error and related issues that can affect the results of biosimilar clinical trials, a study shows.
A new report from Cardinal Health Specialty Solutions gives behind-the-scenes perspectives from oncologists about CAR-T cell therapies, biosimilars and AML therapies (or genomic medicines)

Biosimilars for Cancer Drugs Move AheadBiosimilar to Herceptin Is Approved and Neulasta biosimilar does well in studies.
Prepare for major pipeline developments in diabetes, autoimmune disorders, oncology, and COPD.